Abstract
Myasthenia gravis is a common autoimmune disease in which patients experience weakness primarily in the ocular, respiratory, bulbar, and limb muscles. Although the symptoms of most patients with myasthenia gravis are well controlled with conventional immunotherapies, about 15% of them experience a refractory disease. This systematic review will focus on the safety and efficacy of monoclonal antibodies, specifically rituximab and eculizumab, in treating myasthenia gravis
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
